BioWorld Asia

April 7, 2004

Australia-Based Norwood Seeks IPO On London's AIM Exchange

An Australian company with a U.S. development partner is expecting to float on the Alternative Investment Market in London to raise £15 million (US$27.2 million). (BioWorld International) Read More

Ablynx Completes EUR25M Series B Financing For Nanobody Platform

HIV Research Could Benefit From Immune System Model

Cilian, Evotec Neuroscience Reel In Venture Funding Totaling EUR30M

Ardana Signs New Zentaris Deal, Gains Global Rights To Teverelix

EU Finalizes Environmental Law That Could Leave Biotech Liable

Gastrotech Acquires Lilly Deal Through Purchase Of IP Assets

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 17, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

European Commission floats multiple fixes for MDR, IVDR

BioWorld MedTech

The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.